vs
ICU MEDICAL INC（ICUI）与Penguin Solutions, Inc.（PENG）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Penguin Solutions, Inc.的1.6倍（$540.7M vs $343.1M），Penguin Solutions, Inc.净利率更高（1.5% vs -2.9%，领先4.4%），Penguin Solutions, Inc.同比增速更快（0.6% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $28.2M），过去两年Penguin Solutions, Inc.的营收复合增速更高（11.8% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
企鹅解决方案公司旗下的兰波集团以拉姆齐解决方案品牌开展业务，是一家美国企业，业务涵盖个人理财、领导力发展、人际关系管理与职业发展相关产品与服务。该公司由戴夫·拉姆齐与妻子莎伦于1991年创立，总部位于田纳西州富兰克林。
ICUI vs PENG — 直观对比
营收规模更大
ICUI
是对方的1.6倍
$343.1M
营收增速更快
PENG
高出14.7%
-14.1%
净利率更高
PENG
高出4.4%
-2.9%
自由现金流更多
ICUI
多$7.7M
$28.2M
两年增速更快
PENG
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $343.1M |
| 净利润 | $-15.7M | $5.3M |
| 毛利率 | 37.5% | 28.0% |
| 营业利润率 | 1.0% | 5.7% |
| 净利率 | -2.9% | 1.5% |
| 营收同比 | -14.1% | 0.6% |
| 净利润同比 | 34.0% | 1.0% |
| 每股收益（稀释后） | $-0.63 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIPENG
| Q4 25 | $540.7M | $343.1M | ||
| Q3 25 | $537.0M | $337.9M | ||
| Q2 25 | $548.9M | $324.3M | ||
| Q1 25 | $604.7M | $365.5M | ||
| Q4 24 | $629.8M | $341.1M | ||
| Q3 24 | $589.1M | $284.8M | ||
| Q2 24 | $596.5M | $300.6M | ||
| Q1 24 | $566.7M | — |
净利润ICUIPENG
| Q4 25 | $-15.7M | $5.3M | ||
| Q3 25 | $-3.4M | $9.4M | ||
| Q2 25 | $35.3M | $2.7M | ||
| Q1 25 | $-15.5M | $8.1M | ||
| Q4 24 | $-23.8M | $5.2M | ||
| Q3 24 | $-33.0M | — | ||
| Q2 24 | $-21.4M | $5.6M | ||
| Q1 24 | $-39.5M | — |
毛利率ICUIPENG
| Q4 25 | 37.5% | 28.0% | ||
| Q3 25 | 37.4% | 28.6% | ||
| Q2 25 | 37.9% | 29.3% | ||
| Q1 25 | 34.7% | 28.6% | ||
| Q4 24 | 36.1% | 28.7% | ||
| Q3 24 | 34.8% | 28.8% | ||
| Q2 24 | 34.8% | 29.6% | ||
| Q1 24 | 32.7% | — |
营业利润率ICUIPENG
| Q4 25 | 1.0% | 5.7% | ||
| Q3 25 | 2.6% | 3.7% | ||
| Q2 25 | 1.9% | 3.0% | ||
| Q1 25 | 2.1% | 5.1% | ||
| Q4 24 | 6.0% | 5.1% | ||
| Q3 24 | 1.4% | -1.2% | ||
| Q2 24 | 1.3% | 3.8% | ||
| Q1 24 | -1.9% | — |
净利率ICUIPENG
| Q4 25 | -2.9% | 1.5% | ||
| Q3 25 | -0.6% | 2.8% | ||
| Q2 25 | 6.4% | 0.8% | ||
| Q1 25 | -2.6% | 2.2% | ||
| Q4 24 | -3.8% | 1.5% | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | -3.6% | 1.9% | ||
| Q1 24 | -7.0% | — |
每股收益（稀释后）ICUIPENG
| Q4 25 | $-0.63 | $0.04 | ||
| Q3 25 | $-0.14 | $0.10 | ||
| Q2 25 | $1.43 | $-0.01 | ||
| Q1 25 | $-0.63 | $0.09 | ||
| Q4 24 | $-0.97 | $0.10 | ||
| Q3 24 | $-1.35 | — | ||
| Q2 24 | $-0.88 | $0.10 | ||
| Q1 24 | $-1.63 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $461.5M |
| 总债务越低越好 | — | $462.3M |
| 股东权益账面价值 | $2.1B | $389.7M |
| 总资产 | $4.1B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 1.19× |
8季度趋势，按日历期对齐
现金及短期投资ICUIPENG
| Q4 25 | — | $461.5M | ||
| Q3 25 | — | $453.8M | ||
| Q2 25 | — | $735.5M | ||
| Q1 25 | — | $647.0M | ||
| Q4 24 | $308.6M | $393.7M | ||
| Q3 24 | $312.5M | $389.5M | ||
| Q2 24 | $302.6M | $467.5M | ||
| Q1 24 | $251.4M | — |
总债务ICUIPENG
| Q4 25 | — | $462.3M | ||
| Q3 25 | — | $461.8M | ||
| Q2 25 | — | $659.5M | ||
| Q1 25 | — | $658.8M | ||
| Q4 24 | — | $658.1M | ||
| Q3 24 | — | $657.3M | ||
| Q2 24 | — | $667.0M | ||
| Q1 24 | — | — |
股东权益ICUIPENG
| Q4 25 | $2.1B | $389.7M | ||
| Q3 25 | $2.1B | $394.2M | ||
| Q2 25 | $2.1B | $584.8M | ||
| Q1 25 | $2.0B | $602.5M | ||
| Q4 24 | $2.0B | $400.4M | ||
| Q3 24 | $2.0B | $391.4M | ||
| Q2 24 | $2.0B | $423.4M | ||
| Q1 24 | $2.1B | — |
总资产ICUIPENG
| Q4 25 | $4.1B | $1.6B | ||
| Q3 25 | $4.1B | $1.6B | ||
| Q2 25 | $4.1B | $1.8B | ||
| Q1 25 | $4.2B | $1.8B | ||
| Q4 24 | $4.2B | $1.6B | ||
| Q3 24 | $4.3B | $1.5B | ||
| Q2 24 | $4.3B | $1.5B | ||
| Q1 24 | $4.3B | — |
负债/权益比ICUIPENG
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 1.13× | ||
| Q1 25 | — | 1.09× | ||
| Q4 24 | — | 1.64× | ||
| Q3 24 | — | 1.68× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $31.1M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $28.2M |
| 自由现金流率自由现金流/营收 | 6.6% | 8.2% |
| 资本支出强度资本支出/营收 | 4.6% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 5.89× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $116.3M |
8季度趋势，按日历期对齐
经营现金流ICUIPENG
| Q4 25 | $60.6M | $31.1M | ||
| Q3 25 | $56.7M | $-70.4M | ||
| Q2 25 | $11.2M | $92.8M | ||
| Q1 25 | $51.3M | $72.9M | ||
| Q4 24 | $40.2M | $13.8M | ||
| Q3 24 | $36.1M | — | ||
| Q2 24 | $82.0M | $57.9M | ||
| Q1 24 | $45.8M | — |
自由现金流ICUIPENG
| Q4 25 | $36.0M | $28.2M | ||
| Q3 25 | $27.6M | $-73.4M | ||
| Q2 25 | $-8.5M | $90.9M | ||
| Q1 25 | $36.7M | $70.5M | ||
| Q4 24 | $16.1M | $12.0M | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | $48.9M | ||
| Q1 24 | $29.9M | — |
自由现金流率ICUIPENG
| Q4 25 | 6.6% | 8.2% | ||
| Q3 25 | 5.1% | -21.7% | ||
| Q2 25 | -1.5% | 28.0% | ||
| Q1 25 | 6.1% | 19.3% | ||
| Q4 24 | 2.6% | 3.5% | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | 16.3% | ||
| Q1 24 | 5.3% | — |
资本支出强度ICUIPENG
| Q4 25 | 4.6% | 0.8% | ||
| Q3 25 | 5.4% | 0.9% | ||
| Q2 25 | 3.6% | 0.6% | ||
| Q1 25 | 2.4% | 0.6% | ||
| Q4 24 | 3.8% | 0.5% | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 3.3% | 3.0% | ||
| Q1 24 | 2.8% | — |
现金转化率ICUIPENG
| Q4 25 | — | 5.89× | ||
| Q3 25 | — | -7.47× | ||
| Q2 25 | 0.32× | 34.88× | ||
| Q1 25 | — | 9.02× | ||
| Q4 24 | — | 2.65× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 10.30× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
PENG
| Integrated Memory Segment | $171.6M | 50% |
| Advanced Computing Segment | $115.7M | 34% |
| Optimized LED Segment | $55.7M | 16% |
